BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 17, 2024
See today's BioWorld
Home
» Chemocentryx Falls on Phase III Failure in Crohn's; Vercirnon Misses Endpoint
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Chemocentryx Falls on Phase III Failure in Crohn's; Vercirnon Misses Endpoint
Aug. 26, 2013
By
Jennifer Boggs
No Comments
Chemocentryx Inc. will have to await word from partner Glaxosmithkline plc on the future of vercirnon after the CCR9 antagonist missed its endpoint in the first of four Phase III studies in moderate to severe Crohn's disease.
BioWorld